Prescribing for Dry Eye Disease - Summary - MDSpire

Prescribing for Dry Eye Disease

The Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) III report, which was recently released, includes an updated prescribing algorithm based on DED etiology or pathogenic drivers.

  • By

  • LISA HORNICK, OD, MBA, FAAO

  • July 1, 2025

  • 7 min

Share

Objective:

Emphasize the significance of the TFOS DEWS III report in shaping treatment options.

Key Findings:
  • Include specific examples of therapies for each driver.
Interpretation:

Mention implications for clinical practice.

Limitations:
  • Specify how the lack of clinical trial data affects treatment decisions.
Conclusion:

Reiterate the importance of individualized treatment plans.

Original Source(s)

Prescribing for Dry Eye Disease

  • by LISA HORNICK, OD, MBA, FAAO

  • July 1, 2025

Related Content

Japan Debuts Novel Dry Eye Therapy

Senju Pharmaceutical launches the first TRPV1 antagonist for dry eye in Japan

  • April 30, 2026

  • 3 min
Blending Ocular Health and Aesthetics: Emerging Procedures for Optometric Practice

Eyecare professionals can address functional symptoms of ocular disease, as well as periocular aesthetic care and cosmetic concerns, in both separate and combined treatment frameworks, Selena McGee, OD, FAAO, Janelle Davison, OD, and Shalu Pal, OD, said in their “Beauty in Focus: Elevating Eyecare Through Ocular Aesthetics” presentation at Vision Expo.

Asymptomatic Meibomian Gland Characteristics 

Silent gland failure: what do asymptomatic adults reveal about subclinical MGD?

  • January 14, 2026

  • 3 min